Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Mesothelioma: Between Pragmatism And Hope.

M. Migliore
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Although malignant pleural mesothelioma (MPM) is a rare tumor, it is among one the most discussed tumor in the industrial world. Mesothelioma represents 0.3% of all number of deaths for cancer in the recent GLOBOCAN study (1). The incidence is projected to increase in the next two decades, and the reported dismal 5-year survival rate of less than 5% makes MPM one of the deathliest worldwide tumor (2,3). Some Scientists suggest that the asbestos promotes a chronic pleural inflammatory that after years stimulates the development of a malignant mesothelioma in up to 5% of exposed individuals (4). Patients but also physicians/surgeons are sometimes found lost in the numerous confusing articles on MPM which can be easily taken from internet. Certainly, the source from where the information have been extrapolated is of paramount importance to obtain reliable scientific data on survival and quality of life (5-10), and this should be taken in consideration by the “modern” patient who goes in internet to take information about his/her surgeon and proposed treatment. Nevertheless, although the modern patient is becoming more and more exigent, the mesothelioma patient’s dream, isn’t about which kind of treatment will be used, but about simpler pursuits: patients want undergo to the treatment, surgical or non-surgical, which gives them long term survival, and good quality of life. In the modern real-life it is usual to find patients with MPM who are conducting a battle between the desire to live (hope) and the cruelty given by the large amount of data available on internet saying that the survival is poor (pragmatism) (11). For surgeons and oncologists, although at a different level of sadness, things are similar as we experience the contrast between the scientific evidence that surgery or other treatment does not “cure” MPM but in the same time we feel uncomfortable to deny hope to our patients. So, what is the right thing to do? My personal opinion is that that a more profound dialogue is necessary to understand the pragmatism and hope in MPM in such a way to know where the scale should hang.
This paper references
10.1016/S2213-2600(16)30144-8
Hope persists for mesothelioma advances despite setbacks.
B. Furlow (2016)
10.1016/S1470-2045(18)30100-1
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
10.1007/s12055-017-0606-y
Surgery for mesothelioma: the evidence base and a pragmatic approach to surgical treatment
V. Pai (2017)
10.2217/fon-2018-0835
Mood disorders and outcomes in lung cancer patients undergoing surgery: a brief summery.
M. Signorelli (2020)
10.2217/fon.15.286
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.
M. Migliore (2015)
10.1016/S0169-5002(16)30212-4
195 A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study
E. Lim (2016)
10.2217/fon.15.225
Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history?
T. Treasure (2015)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
10.1016/j.jtcvs.2017.10.070
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10‐year experience
M. Ambrogi (2018)
10.1016/J.HOC.2005.09.003
Mesothelioma from the patient's perspective.
H. Clayson (2005)
State of the Art review - Surgery in Malignant Pleural Mesothelioma
R Bueno (2018)
Figure 1 Tip the balance in malignant pleural mesothelioma. Expertise in Malignant Pleural Mesothelioma
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
of Clinical Oncology clinical practice guideline
H L Kindler (2018)
10.1016/S0140-6736(14)60418-9
Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
R. Rintoul (2014)
10.1016/j.jtcvs.2017.12.131
Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma
H. Batırel (2018)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/S0140-6736(14)60795-9
Surgical resection of mesothelioma: an evidence-free practice
Y. Lee (2014)
10.1016/j.jtho.2018.06.011
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
L. Mutti (2018)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.3322/caac.21490
Improving patient and caregiver outcomes in oncology: Team‐based, timely, and targeted palliative care
D. Hui (2018)
10.2217/fon.14.256
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: preliminary experience.
M. Migliore (2015)
Debulking Surgery and Hyperthermic Chemotherapy for pleural mesothelioma : a pilot study
M Migliore
10.1186/s12885-018-5064-4
Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma
R. Schwartz (2018)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.1016/S1470-2045(18)30868-4
Checkpoint inhibitors in mesothelioma: hope for the future?
A. Bibby (2019)
Debulking Surgery and Hyperthermic Chemotherapy for pleural mesothelioma: a pilot study. ISRCTN12709516
M Migliore
10.1200/JCO.2017.76.6394
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
H. Kindler (2018)
10.1007/978-3-662-05225-9_8
Lung Cancer and Pleural Mesothelioma
R. Parker (2003)
10.2217/fon.15.259
The Second Mediterranean Symposium: considering mesothelioma from a local and international perspective.
T. Treasure (2015)
10.21037/jtd.2017.10.16
Surgery for malignant pleural mesothelioma: an international guidelines review.
S. Ricciardi (2018)
10.1136/thoraxjnl-2013-203846
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position
A. Datta (2013)
10.2217/fon.15.184
Is the patient with mesothelioma without hope?
A. Maat (2015)



Semantic Scholar Logo Some data provided by SemanticScholar